KBC Group NV Buys 5,155 Shares of Organon & Co. (NYSE:OGN)

KBC Group NV boosted its stake in Organon & Co. (NYSE:OGN) by 66.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,899 shares of the company’s stock after buying an additional 5,155 shares during the quarter. KBC Group NV’s holdings in Organon & Co. were worth $192,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Squarepoint Ops LLC bought a new stake in shares of Organon & Co. in the 2nd quarter worth about $671,000. Cetera Investment Advisers boosted its position in Organon & Co. by 2.4% in the second quarter. Cetera Investment Advisers now owns 58,599 shares of the company’s stock valued at $1,213,000 after buying an additional 1,378 shares in the last quarter. SG Americas Securities LLC grew its stake in Organon & Co. by 161.1% during the third quarter. SG Americas Securities LLC now owns 22,689 shares of the company’s stock worth $434,000 after buying an additional 14,000 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in shares of Organon & Co. by 6.6% during the third quarter. Handelsbanken Fonder AB now owns 68,250 shares of the company’s stock worth $1,306,000 after buying an additional 4,250 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Organon & Co. by 57.6% in the third quarter. GAMMA Investing LLC now owns 6,362 shares of the company’s stock valued at $122,000 after acquiring an additional 2,326 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Trading Up 0.4 %

OGN opened at $14.98 on Wednesday. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The stock has a market capitalization of $3.86 billion, a PE ratio of 2.97, a PEG ratio of 0.87 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a 50-day moving average price of $15.43 and a two-hundred day moving average price of $17.80.

Wall Street Analyst Weigh In

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.